Ctrl K

Lobbying client

Pharmaceutical Research and Manufacturers of America (Phrma)

Lobbies Congress with its own staff and reports its total lobbying expense, which includes anything it paid outside firms.

Reported spend, this Congress
$64.5M
Outside firms hired
29
Bills named in its reports
126
Issue areas
9

Spending by quarter, 2026

$12.2M
Q1 2026
$7.4M
Q2 2026
$7.0M
Q3 2026
—
Q4 2026

Earlier this Congress: Q1 2025 $12.9M · Q2 2025 $7.6M · Q3 2025 $9.0M · Q4 2025 $8.4M

Issues it lobbied on

9
Health Issues 117Pharmacy 63Medicare/Medicaid 61Copyright/Patent/Trademark 52Trade (domestic/foreign) 42Budget/Appropriations 27Defense 9Foreign Relations 2Taxation/Internal Revenue Code 2

Bills named in its reports

126
BillStatusReportsLatest
HR.1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.In Committee59Q3 2026
S.832Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025In Committee41Q3 2026
S.1040Drug Competition Enhancement ActIntroduced31Q3 2026
S.1041Affordable Prescriptions for Patients ActIntroduced28Q3 2026
HR.1An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.Signed24Q3 2026
S.1097Interagency Patent Coordination and Improvement Act of 2025Introduced19Q3 2026
S.1095Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or theIntroduced18Q3 2026
S.1096Preserve Access to Affordable Generics and Biosimilars ActIntroduced17Q3 2026
HR.2214DRUG ActIn Committee14Q3 2026
HR.5376Impacts and Outcomes for Health Career Training ActIn Committee13Q3 2026
HR.3160Promoting and Respecting Economically Vital American Innovation Leadership Act or the PREVAIL ActIn Committee12Q3 2026
S.1414Expedited Access to Biosimilars ActIntroduced12Q3 2026
S.1553Promoting and Respecting Economically Vital American Innovation Leadership Act or the PREVAIL ActIn Committee12Q3 2026
S.2658Medication Affordability and Patent Integrity ActIntroduced12Q3 2026
S.43Skinny Labels, Big Savings ActIn Committee12Q3 2026
S.891Bipartisan Health Care ActIn Committee12Q3 2026
S.1954Biosimilar Red Tape Elimination ActIntroduced11Q3 2026
S.864HELP Copays ActIn Committee11Q3 2026
HCONRES.14Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.Introduced10Q2 2026
HR.3269ETHIC ActIn Committee10Q3 2026
HR.4299Protecting Patient Access to Cancer and Complex Therapies ActIn Committee8Q3 2026
HR.946Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures ActIntroduced8Q3 2026
S.2296National Defense Authorization Act for Fiscal Year 2026Introduced8Q3 2026
S.3345PBM Price Transparency and Accountability ActIn Committee8Q3 2026
S.355FDA Modernization Act 3.0Introduced8Q3 2026
HR.1262Give Kids a Chance Act of 2025Introduced7Q2 2026
HR.4317PBM Reform Act of 2025In Committee7Q3 2026
HR.5378Tribal Healthcare Careers ActIn Committee7Q3 2026
HR.6283FOSTER ActIn Committee7Q3 2026
HR.6485Skinny Labels, Big Savings ActIn Committee7Q3 2026
HR.830Save Americans from the Fentanyl Emergency Act or the SAFE ActIn Committee7Q3 2026
HR.890Stopping Pharma’s Ripoffs and Drug Savings For All ActIn Committee7Q3 2026
S.1542Uyghur Policy Act of 2026Introduced7Q3 2026
S.2256Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026Introduced7Q3 2026
S.527Prescription Pricing for the People Act of 20Introduced7Q3 2026
S.652Protecting Patients from Deceptive Drug Ads ActIn Committee7Q3 2026
HR.2213Medical Supply Chain Resiliency ActIn Committee6Q3 2026
HR.3152Patent Eligibility Restoration Act of 2025In Committee6Q3 2026
HR.4121Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026Introduced6Q3 2026
S.1546Patent Eligibility Restoration Act of 2025In Committee6Q3 2026
S.2276ETHIC ActIn Committee6Q3 2026
S.2620Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY ActIn Committee6Q3 2026
S.932Give Kids a Chance Act of 2025In Committee6Q1 2026
HR.1574Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 or the RESTORE Patent Rights Act of 2025In Committee5Q1 2026
HR.4570Interagency Patent Coordination and Improvement Act of 2025In Committee5Q3 2026
HR.5256340B ACCESS ActIn Committee5Q3 2026
HR.5304Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026Introduced5Q3 2026
HR.5342Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026Introduced5Q3 2026
HR.7148Consolidated Appropriations Act, 2026Signed5Q3 2026
HR.8646Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027Introduced5Q3 2026
HRES.566Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14.Introduced5Q2 2026
S.1071National Defense Authorization Act for Fiscal Year 2026Signed5Q3 2026
S.2354Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026Introduced5Q3 2026
S.2587Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026Introduced5Q3 2026
S.3014Ensuring Timely Access to Generics Act of 2025In Committee5Q3 2026
S.3788Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act or the CLEAR LABELS ActIntroduced5Q3 2026
S.4784National Defense Authorization Act for Fiscal Year 2027Introduced5Q3 2026
S.708Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 or the RESTORE Patent Rights Act of 2025In Committee5Q1 2026
HR.3838Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026Introduced4Q4 2025
HR.3944Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026Introduced4Q1 2026
HR.4213Department of Homeland Security Appropriations Act, 2026Introduced4Q1 2026
HR.4780Use Sovereignty To reduce Rx Act or the USTRx ActIn Committee4Q3 2026
HR.5526Biosimilar Red Tape Elimination ActIn Committee4Q3 2026
HR.6423HELP Copays ActIn Committee4Q3 2026
HR.7953FAIR ACTIn Committee4Q3 2026
HR.8800National Defense Authorization Act for Fiscal Year 2027Introduced4Q3 2026
HR.9260Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027Introduced4Q3 2026
HR.2821FDA Modernization Act 3.0Introduced3Q4 2025
HR.5371Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026Signed3Q2 2026
HR.6938Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026Signed3Q3 2026
HR.7837Most Favored Patient Act of 2026In Committee3Q3 2026
HR.8269CLEAR LABELS ActIn Committee3Q3 2026
HR.9661Expedited Access to Biosimilars ActIn Committee3Q3 2026
S.1302Increasing Transparency in Generic Drug Applications ActIn Committee3Q4 2025
S.1637Medicaid VBPs for Patients Act or the MVP ActIn Committee3Q1 2026
SCONRES.7An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.Introduced3Q1 2025
HR.1968Full-Year Continuing Appropriations and Extensions Act, 2025Signed2Q1 2025
HR.3521Clinical Trial Modernization ActIn Committee2Q3 2026
HR.4Rescissions Act of 2025Signed2Q2 2026
HR.6610Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]Introduced2Q3 2026
HR.6624Biological Intellectual Property Protection Act of 2025Introduced2Q3 2026
HR.7391Community Health Center Drug Pricing Protection ActIn Committee2Q3 2026
HR.9102BINSA ActIn Committee2Q3 2026
HR.9142Prohibiting Adversarial Patents Act of 2026In Committee2Q3 2026
HR.9504Tax Exempt Hospital Transparency ActIntroduced2Q3 2026
S.1387National Biotechnology Initiative Act of 2025In Committee2Q3 2026
S.3452Biological Intellectual Property Protection Act of 2025In Committee2Q3 2026
S.705Innovation in Pediatric Drugs Act of 2025In Committee2Q1 2025
S.839Safeguarding Honest Speech ActIn Committee2Q3 2025
HR.10628Biosimilars Access and Affordability ActIn Committee1Q3 2026
HR.1843To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.In Committee1Q4 2025
HR.2715Destruction of Hazardous Imports ActIn Committee1Q2 2026
HR.2882Central Coast of California Conservation Act of 2025In Committee1Q1 2025
HR.3701Family Vaccine Protection ActIn Committee1Q2 2025
HR.4132Prescription Information Modernization Act of 2025In Committee1Q2 2025
HR.4370SAMS Act of 2025In Committee1Q1 2025
HR.6089Biomanufacturing Excellence Act of 2025In Committee1Q2 2026
HR.6500Continuing Appropriations and Extensions Act, 2027Signed1Q3 2026
HR.6509Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025 or the SAFE Drugs Act of 2025In Committee1Q3 2026
HR.7140CLEAR ActIn Committee1Q1 2026
HR.8574U.S. in Expos ActIn Committee1Q2 2025
HR.8845Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027Introduced1Q2 2026
HR.9026To designate the facility of the United States Postal Service located at 80 Atlantic Avenue in Oceanside, New York, as the "Detective Luis G. Alvarez Post Office".Introduced1Q1 2025
HR.9027Military and Veterans Fuel Discount Act of 2026In Committee1Q1 2025
HR.9029Coal Cleanup Taxpayer Protection Act of 2026In Committee1Q1 2025
HR.9310Department of Homeland Security Appropriations Act, 2027Introduced1Q2 2026
HR.950Saving Seniors Money on Prescriptions ActIn Committee1Q1 2025
HR.9599SECURE 340B ActIn Committee1Q3 2026
S.1784Mapping America’s Pharmaceutical Supply Act or the MAPS ActIn Committee1Q2 2025
S.2Secure America ActSigned1Q2 2026
S.2220Fighting for the Overlooked Recognition of Groups Operating in Toxic Test Environments in Nevada (FORGOTTEN) Veterans Act of 2025In Committee1Q1 2025
S.2710Open Payments Expansion ActIn Committee1Q4 2025
S.2780No Tax on Large Party Tips ActIn Committee1Q2 2025
S.3794Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026 or the SAFE Drugs Act of 2026Introduced1Q3 2026
S.4023America’s Living Library ActIn Committee1Q1 2026
S.4098Artificial Intelligence-Ready Data ActIn Committee1Q1 2026
S.4189INSULIN Act of 2026Introduced1Q3 2026
S.4690Encouraging Public Offerings Act of 2026In Committee1Q1 2025
S.4795FREEDOM ActIn Committee1Q1 2025
S.4942SAFE Banking Act of 2026In Committee1Q1 2025
S.5043Secure Drug Supply Chain Act of 2026In Committee1Q3 2026
S.5244SUSTAIN 340B ActIn Committee1Q3 2026
S.5265USTRx ActIn Committee1Q3 2026
S.5316BINSA ActIn Committee1Q3 2026
S.5571A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.In Committee1Q3 2026
S.863Genomic Data Protection ActIn Committee1Q3 2025

Who lobbied for it

30
RegistrantReportedLatest
Pharmaceutical Research and Manufacturers of AmericaIn-house$64.5MQ3 2026
Arnold & Porter Kaye Scholer LLPOutside firm$2.3MQ3 2026
Covington & Burling LLPOutside firm$1.9MQ3 2026
Akin Gump Strauss Hauer & FeldOutside firm$840KQ3 2026
East End Group, LLCOutside firm$525KQ3 2026
Todd Strategy GroupOutside firm$480KQ3 2026
DLA Piper LLP (US)Outside firm$420KQ3 2026
W Strategies, LLCOutside firm$420KQ3 2026
Aegis LLCOutside firm$420KQ3 2026
The Mcmanus GroupOutside firm$420KQ3 2026
Miller Strategies, LLCOutside firm$420KQ3 2026
Crossroads Strategies, LLCOutside firm$360KQ3 2026
Empire Consulting GroupOutside firm$350KQ3 2026
Farragut Partners LLPOutside firm$350KQ3 2026
Lesic and Camper CommunicationsOutside firm$350KQ3 2026
BGR Government AffairsOutside firm$350KQ3 2026
Capitol Counsel LLCOutside firm$320KQ3 2026
SL Strategies, LLCOutside firm$315KQ3 2026
Advanced Policy Consulting, LLCOutside firm$280KQ3 2026
Marshall & Popp, LLCOutside firm$280KQ3 2026
Thorn Run PartnersOutside firm$270KQ3 2026
YC Consulting, LLCOutside firm$260KQ3 2026
Bravo GroupOutside firm$250KQ3 2026
Desimone Consulting, LLCOutside firm$220KQ3 2026
Radius Advocacy, LLCOutside firm$210KQ3 2026
LMH Strategic SolutionsOutside firm$210KQ3 2026
Tiber Creek Health Strategies, Inc.Outside firm$200KQ1 2026
OGROutside firm$20KQ1 2025
Bose Public Affairs GroupOutside firm$20KQ3 2026
The Simmons & Russell Group, LLCOutside firmUnder $5KQ1 2025

Reports

60

From Lobbying Disclosure Act reports filed with Congress. Each quarter counts once per organization: its own in-house report when it filed one, which already includes what it paid outside firms, otherwise the sum of its firms' reports. Amended reports replace the original. Firms report nothing under $5,000 a quarter. Reports name the bills lobbied on but not how the money was split between them, so bills show organizations, not dollars.

Pharmaceutical Research and Manufacturers of America (Phrma) · Lobbying